Hepatitis C Virus Antibody ELISA Test Kit Market Size, Share, Trends & Forecast

The Hepatitis C Virus Antibody ELISA Test Kit Market is expanding as hepatitis C screening and diagnostic programs receive greater attention worldwide. The market was valued at USD 1.087 billion in 2025 and is projected to reach USD 1.5 billion by 2035, growing at a 3.2% CAGR during 2026–2035.

Diagnostic technology is advancing through automated ELISA systems, improved sensitivity, faster processing, and digital laboratory workflows. These developments are helping laboratories handle larger testing volumes while supporting more consistent detection of HCV antibodies.

Clinical diagnostics represents the largest application area, followed by research laboratories and blood donation screening. The product landscape includes sandwich, competitive, and indirect ELISA kits, with each format serving different testing and laboratory requirements.

Hospitals, diagnostic laboratories, and blood banks are the major end users, while direct sales, online retail, and third-party distributors support product availability. North America currently leads the market, while Asia-Pacific is expected to see strong growth as healthcare investment and screening programs expand.

Future opportunities are emerging through AI-assisted diagnostics, point-of-care testing, faster screening technologies, and expanded testing in underserved regions. Partnerships with healthcare providers and public-health organizations could also support broader access to HCV diagnostic solutions.